Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial

医学 肝硬化 意向治疗分析 肝移植 随机对照试验 门脉高压 内科学 人口 外科 经颈静脉肝内门体分流术 胃肠病学 移植 环境卫生
作者
Yong Lv,Zhiping Yang,Lei Liu,Kai Li,Chuangye He,Zhenyu Wang,Wei Bai,Wengang Guo,Tianlei Yu,Xulong Yuan,Hongbo Zhang,Huahong Xie,Liping Yao,Jianhong Wang,Tao Li,Qiuhe Wang,Hui Chen,Enxin Wang,Dongdong Xia,Bohan Luo
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:4 (8): 587-598 被引量:217
标识
DOI:10.1016/s2468-1253(19)30090-1
摘要

Background The survival benefit of early placement of transjugular intrahepatic portosystemic shunts (TIPS) in patients with cirrhosis and acute variceal bleeding is controversial. We aimed to assess whether early TIPS improves survival in patients with advanced cirrhosis and acute variceal bleeding. Methods We did an investigator-initiated, open-label, randomised controlled trial at an academic hospital in China. Consecutive patients with advanced cirrhosis (Child-Pugh class B or C) and acute variceal bleeding who had been treated with vasoactive drugs plus endoscopic therapy were randomly assigned (2:1) to receive either early TIPS (done within 72 h after initial endoscopy [early TIPS group]) or standard treatment (vasoactive drugs continued to day 5, followed by propranolol plus endoscopic band ligation for the prevention of rebleeding, with TIPS as rescue therapy when needed [control group]). Randomisation was done by web-based randomisation system using a Pocock and Simon's minimisation method with Child-Pugh class (B vs C) and presence or absence of active bleeding as adjustment factors. The primary outcome was transplantation-free survival, analysed in the intention-to-treat population, excluding individuals subsequently found to be ineligible for enrolment. This study is registered with ClinicalTrials.gov, number NCT01370161, and is completed. Findings From June 26, 2011, to Sept 30, 2017, 373 patients were screened and 132 patients were randomly assigned to the early TIPS group (n=86) or to the control group (n=46). After exclusion of three individuals subsequently found to be ineligible for enrolment (two patients in the early TIPS group with non-cirrhotic portal hypertension or hepatocellular carcinoma, and one patient in the control group due to non-cirrhotic portal hypertension), 84 patients in the early TIPS group and 45 patients in the control group were included in the intention-to-treat population. 15 (18%) patients in the early TIPS group and 15 (33%) in the control group died; two (2%) patients in the early TIPS group and one (2%) in the control group underwent liver transplantation. Transplantation-free survival was higher in the early TIPS group than in the control group (hazard ratio 0·50, 95% CI 0·25–0·98; p=0·04). Transplantation-free survival at 6 weeks was 99% (95% CI 97–100) in the early TIPS group compared with 84% (75–96; absolute risk difference 15% [95% CI 5–48]; p=0·02) and at 1 year was 86% (79–94) in the early TIPS group versus 73% (62–88) in the control group (absolute risk difference 13% [95% CI 2–28]; p=0·046). There were no significant differences between the two groups in the incidence of hepatic hydrothorax (two [2%] of 84 patients in the early TIPS group vs one [2%] of 45 in the control group; p=0·96), spontaneous bacterial peritonitis (one [1%] vs three [7%]; p=0·12), hepatic encephalopathy (29 [35%] vs 16 [36%]; p=1·00), hepatorenal syndrome (four [5%] vs six [13%]; p=0·10), and hepatocellular carcinoma (four [5%] vs one [2%]; p=0·68). There was no significant difference in the number of patients who experienced other serious adverse events (ten [12%] vs 11 [24%]; p=0·07) or non-serious adverse events (21 [25%] vs 19 [42%]; p=0·05) between groups. Interpretation Early TIPS with covered stents improved transplantation-free survival in selected patients with advanced cirrhosis and acute variceal bleeding and should therefore be preferred to the current standard of care. Funding National Natural Science Foundation of China, National Key Technology R&D Program, Optimized Overall Project of Shaanxi Province, Boost Program of Xijing Hospital.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
量子星尘发布了新的文献求助10
1秒前
取名叫做利完成签到 ,获得积分10
2秒前
2秒前
贪玩钢铁侠完成签到,获得积分10
3秒前
hongw_liu发布了新的文献求助10
3秒前
无奈镜子完成签到 ,获得积分10
3秒前
Xu完成签到,获得积分10
4秒前
微笑惜海完成签到,获得积分20
4秒前
可耐的紫夏完成签到,获得积分10
4秒前
出其东门完成签到,获得积分10
4秒前
lvwubin完成签到,获得积分10
4秒前
4秒前
4秒前
时尚的梦曼完成签到,获得积分10
5秒前
量子星尘发布了新的文献求助10
5秒前
苏休夫发布了新的文献求助10
5秒前
沉默问夏完成签到 ,获得积分10
5秒前
wd发布了新的文献求助10
6秒前
王佳豪发布了新的文献求助10
6秒前
认真浩宇完成签到,获得积分10
7秒前
伴征阳完成签到 ,获得积分10
7秒前
热心的小馒头完成签到 ,获得积分10
7秒前
suesue完成签到,获得积分10
7秒前
7秒前
阿奇霉素完成签到 ,获得积分20
8秒前
amberzyc应助何双采纳,获得10
8秒前
RunsenXu完成签到,获得积分10
8秒前
木木完成签到,获得积分10
8秒前
听话的文涛完成签到,获得积分10
9秒前
Zoe完成签到,获得积分10
9秒前
logan完成签到,获得积分0
9秒前
缓慢千易完成签到,获得积分10
10秒前
wjr完成签到,获得积分10
10秒前
独自受罪完成签到 ,获得积分10
10秒前
lzx完成签到,获得积分10
10秒前
懵懂的琦完成签到 ,获得积分10
11秒前
Sci完成签到,获得积分20
11秒前
ruandb完成签到,获得积分10
11秒前
沉舟完成签到 ,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Binary Alloy Phase Diagrams, 2nd Edition 8000
Building Quantum Computers 800
Translanguaging in Action in English-Medium Classrooms: A Resource Book for Teachers 700
Natural Product Extraction: Principles and Applications 500
Exosomes Pipeline Insight, 2025 500
Qualitative Data Analysis with NVivo By Jenine Beekhuyzen, Pat Bazeley · 2024 500
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5664967
求助须知:如何正确求助?哪些是违规求助? 4873787
关于积分的说明 15110464
捐赠科研通 4824067
什么是DOI,文献DOI怎么找? 2582622
邀请新用户注册赠送积分活动 1536541
关于科研通互助平台的介绍 1495147